Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2021-12-15 Regulatory Filings
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics AS - New name registered
Regulatory Filings Classification · 95% confidence The document is a very short announcement (492 characters) stating that the company's name change (from Vaccibody AS to Nykode Therapeutics AS) has been officially registered and that the ticker symbol will also change. This is a specific corporate action announcement that does not fit the definitions for 10-K, ER, IR, or AGM-R. It is not a report publication announcement (RPA) because it is announcing a completed administrative action, not the release of a financial report. Since there is no specific category for a 'Name Change Announcement,' and it is a general regulatory update regarding corporate identity, the most appropriate fallback category is Regulatory Filings (RNS).
2021-12-15 Norwegian
Vaccibody AS*) – Notice of Extraordinary General Meeting
AGM Information Classification · 100% confidence The document is explicitly titled "INNKALLING TIL EKSTRAORDINÆR GENERALFORSAMLING I VACCIBODY AS" (Notice of Extraordinary General Meeting in Vaccibody AS) and contains an agenda for the meeting, including proposals for board changes and remuneration. This clearly indicates it is a formal notice sent to shareholders to convene a meeting. This aligns perfectly with the definition of materials shared during a General Meeting, which falls under AGM Information (AGM-R). Although it is a notice, it is the primary document detailing the meeting's purpose, unlike a simple Report Publication Announcement (RPA) which usually just announces the release of another document. Since it is a notice for an Extraordinary General Meeting, AGM-R is the most specific fit.
2021-12-15 Norwegian
Vaccibody AS*) – Notice of Extraordinary General Meeting
AGM Information Classification · 100% confidence The document is explicitly titled "INNKALLING TIL EKSTRAORDINÆR GENERALFORSAMLING I VACCIBODY AS" (Notice of Extraordinary General Meeting in Vaccibody AS). It details the date, time, location, and agenda for a shareholder meeting, including proposals for board changes and remuneration. This content directly corresponds to the purpose of materials distributed to shareholders to convene a meeting, which aligns best with the definition of materials related to an Annual General Meeting (AGM) or a similar shareholder meeting. Since it is a notice calling for an *Extraordinary* General Meeting, and the closest specific code related to general meetings is AGM-R (AGM Information), this is the most appropriate classification, as it contains the core information for the meeting itself, rather than just a proxy solicitation (PSI) or voting results (DVA).
2021-12-15 English
Vaccibody AS*) – Notice of Extraordinary General Meeting
AGM Information Classification · 98% confidence The document is explicitly titled "Company Announcement" and specifically calls for an "Extraordinary General Meeting (EGM)". It details the date, time, location, and agenda items for this meeting, which include the election of a new board chair and remuneration. The text states, "The notice of the EGM is attached." This structure—a brief announcement calling for a meeting and referencing attached materials—strongly suggests this is not the full AGM presentation or the final voting results, but rather the official notice or proxy material preparation. Since the agenda involves board changes and remuneration, and it is a formal meeting notice, it aligns best with the general scope of an Annual General Meeting (AGM-R) or the materials leading up to it. Given the options, 'AGM-R' (AGM Information) is the most appropriate fit for a formal notice and materials related to a General Meeting, even if it is an Extraordinary one.
2021-12-15 English
Vaccibody AS*) – Notice of Extraordinary General Meeting
AGM Information Classification · 95% confidence The document is explicitly titled 'Vaccibody AS – Notice of Extraordinary General Meeting' and calls for an EGM to be held on December 22, 2021, with specific agenda items related to board changes and remuneration. This clearly indicates it is a formal announcement related to a shareholder meeting, specifically an Extraordinary General Meeting (EGM). The definition for AGM Information (AGM-R) covers presentations and materials shared during the Annual General Meeting (AGM). While this is an EGM, the closest and most appropriate category covering formal meeting notices and related materials is AGM-R, as there is no specific EGM code, and it relates to shareholder governance meetings. Furthermore, the document states, 'The notice of the EGM is attached,' suggesting this text is the announcement itself, not the full presentation or minutes. However, given the content is the notice and agenda for the meeting, AGM-R is the best fit among the provided options for governance meeting materials.
2021-12-15 English
New chairman at Nykode Therapeutics as the Company enters a new stage of internationalization
Board/Management Information Classification · 100% confidence The document is a formal company announcement titled "New chairman at Nykode Therapeutics as the Company enters a new stage of internationalization." It details the proposed election of a new chairman (Martin Nicklasson) and the continuation of an existing board member (Anders Tuv) at an upcoming Extraordinary General Meeting (EGM). This content directly relates to changes in the company's board of directors and senior management structure. This aligns perfectly with the definition for Board/Management Information (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (PSI), but specifically an announcement about board composition changes.
2021-12-15 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.